TLE2

Across TCGA pan-cancer cohorts, TLE2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TLE2 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher TLE2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TLE2 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LSCC, LUAD, and CCRCC are the cancer types where TLE2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	III,IV	0.970	0.223	.004	22	view →
LUAD	DFS	Quartile	All	0.840	1.000	.001	13	view →
CCRCC	DFS	Median	All	0.266	0.931	.003	12	view →
UCEC	DFS	Median	III,IV	0.333	0.880	.018	8	view →
PDAC	OS	Quartile	All	0.213	0.929	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TLE2–LSCC (DFS)

Open the LSCC breakdown →